Modern basal insulin therapy the analogs of insulin types II in the management diabetes mellitus type 2 from the results of clinical trials to real clinical practice

• Alexander S. Ametov
• Natalya A. Chernikova

Abstract

It should be emphasized that among the existing methods of treatment of diabetes mellitus insulin therapy is of particular importance. Long duration type 2 diabetes with persistent hyperglycemia lead to decline products β-cell insulin, thus signaling the development of relative insulin deficiency. In type 1 diabetes on a background of absolute insulin defidency, insulin is the only possible method of treating this group of patients. Obtaining human insulin analog with modern genetic engineering techniques to improve the quality of diabetes management. Basal insulin analogs have a smoother profile, a Longer duration of action than traditional basal insulins, proven efficacy and safety. The appearance of new basal insulin may improve existing therapy due to a prolonged and sustained action at one injection, comparable glycemic control, less risk of hypoglycemia and less weight gain.

Keywords:insulin, diabetes mellitus, clinical practice, basal insulin analogs, insulin glargine U-100, insulin glargine U-300

References

1. IDF Diabetes Atlas. 9^th edition; 2019 Update.

2. Ametov A. S. Type 2 diabetes. Problems and solutions. Moscow: GEOTAR-Media; 2011: 254-87. (in Russian)

3. Goldberg R. B., Holman R., Drucker D.J. Clinical decisions. Management of type 2 diabetes. N Engl J Med. 2008; 358: 293-7. doi: 10.1056/NEJMclde0708469

4. Davidson M.B. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care. 2005; 28: 222-4.

5. Naik.R.G., Palmer J.P. Latent autoimmune diabetes in adults (LADA). Latent autoimmune diabetes in adults. Rev Endocr Metab Disord. 2003; 4: 233-41.

6. Chernikova N.A., Antsiferov M.B. Role and place of hypoglycemia in the management of type 2 diabetes mellitus. Farmateka. 2013; (16): 27-32. (in Russian)

7. Ametov A. S., Chernikova N.A., Antsiferov M. B. Basal insulin therapy: experience in clinical practice. Farmateka. 2013; (16): 37-41. (in Russian)

8. Mauricio D., Meneghini L., Seufert J., et al. Glycaemic controland hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017; 19: 115564.

9. Pettus J., Santos Cavaiola T., Tamborlane W.V., et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016; 32: 478-96.

10. White N.H., Chase H.P., Arslanian S., Tamborlane W.V. 4030 Study Group. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care. 2009; 32 (3): 387-93.

11. Rosenstock J., Cheng A., Ritzel R., Bosnyak Z., Devisme C., Cali A.M.G., et al. More similarities than differences testing insulin glargine 300 Units/mL versus insulin degludec 100 Units/mL in insulin-naive type 2 Diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018; 41: 2147-54. https://doi.org/10.2337/dc18-0559

12. Roussel R., Ritzel R., Boelle-Le Corfec E., et al. Clinicalperspectives from the BEGIN and EDITION programmes: trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. Diabetes Metab. 2018; 44: 402-9.

13. Riddle M.C., Bolli G.B., Ziemen M., Muehlen-Bartmer I., Bizet F., Home P. D. New insulin glargine300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtimeinsulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014; 37: 2755-62.

14. Yki-Jarvinen H., Bergenstal R., Ziemen M., Wardecki M., Muehlen-Bartmer I., et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014; 37 (12): 3235-43.

15. Bolli G.B., Riddle M.C., Bergenstal R.M., Ziemen M., Sestakauskas K., Goyeau H., et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015; 17 (4): 386-94.

16. Kawaguchi Y., Sawa J., Sakuma N., et al. Efficacy and safety ofinsulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: a randomized, open-label, cross-overstudy using continuous glucose monitoring profiles. J Diabetes Investig. 2018. https://doi.org/10.1111/jdi.12884/

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)